DMYD-B.ST Diamyd Medical AB (publ) Series B Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
15:37
Feb 07
Feb 07
Long DMYD B into March 2026 Phase 3 binary data
The author is long Diamyd Medical (DMYD B) ahead of Phase 3 topline results due in March 2026, arguing that positive data could support an Accelerated Approval/BLA filing and drive a +100–300% gap up or attract a buyout at a premium. The causal mechanism is binary clinical data in a precision-medicine subgroup (HLA DR3-DQ2), with valuation support from Sanofi's $2.9B purchase of competitor Provention Bio/Tzield versus Diamyd's ~$200M market cap. The author states the main risk is that bad data sends the stock down -80% to cash value.
HIGH
About DMYD-B.ST Investor Commentary
Across the available history and selected sources, Buzzberg tracks DMYD-B.ST (Diamyd Medical AB (publ) Series B) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Ok-Tomato261.